三阴性乳腺癌的治疗进展

伟 张(太和县人民医院，中国)
孟先 任(太和县人民医院，中国)
冬 刘(太和县人民医院，中国)
友飞 赵(太和县人民医院，中国)
飞 周(太和县人民医院，中国)

摘要

由于三阴性乳腺癌患者预后较差，所以论文总结近年来三阴性乳腺癌（TNBC）综合治疗的研究进展，以提高对该病的认识和治疗水平。TNBC 因其治疗缺乏靶向受体，较其他分型的乳腺癌具有侵袭性强、复发转移早的特点，治疗方案目前仍为手术治疗为主，辅以化疗、放疗等的综合治疗。随着分子机制研究的不断深入，包括雄激素受体阳性的内分泌治疗、靶向药物治疗等为 TNBC 的治疗提供了一些新的想法。　

关键词

三阴性乳腺癌；治疗方案；治疗进展

参考

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018(01): 7-30.

Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014(07): 279-289.

曹志宇 , 何建苗 , 杨波 , 等 . 局部晚期乳腺癌新辅助化疗联合保乳手术的临床疗效观 : 附 81 例报告 [J]. 解放军医学杂志 ,2015(06):488-491.

Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007(08): 2329-2334.

Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. [J] Natl Compr Canc Netw, 2017(04): 433-451.

Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A multicenter phase Ⅱ clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. [J] Clin Oncol,2015(17): 1902-1909.

Chen L, Zhang J, Chen J, et al. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. Oncotarget, 2017(26): 42917- 42925.

Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat, 2018(03): 671-686.

Yang Q, Xu ZH, Zheng LP, et al. Multimodal detection of PDL1: reasonable biomarkers for immune checkpoint in hibitor. Am J Cancer Res, 2018(09): 1689-1696.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i5.5298